Plasma Collection Stocks
Fractionation and collection specialists operate the capital-intensive infrastructure required to convert human plasma into life-saving therapeutic proteins for rare disease and immunology markets. Revenue models rely on a high-volume throughput of donors, utilizing specialized medical hardware and integrated payment processing systems to manage donor compensation and collection efficiency.
As of Oct 23, 2026, Plasma Collection has 6 US-listed companies worth $78.9B combined. The median member moved +0.2% over the past week; TAK led at +2.9% and GRFS trailed at -1.0%.
Companies in Plasma Collection
- TAK – Takeda Pharmaceutical Co Ltd ADR, $64.7B
- HAE – Haemonetics Corporation, $5.4B
- GRFS – Grifols SA ADR, $5.2B
- ADMA – ADMA Biologics Inc, $2.4B
- PAYS – Paysign Inc, $803M
- KMDA – Kamada, $466M